AWD 52-39

Last updated

AWD 52-39
AWD52-39 structure.png
Clinical data
Other namesN,N-Diacetoxyethyl-9,10-dihydrolysergamide
Drug class Nootropic; Serotonin receptor modulator
ATC code
  • None
Identifiers
  • 2-[2-acetyloxyethyl-[(6aR,9R)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carbonyl]amino]ethyl acetate
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
Formula C24H31N3O5
Molar mass 441.528 g·mol−1
3D model (JSmol)
  • CC(=O)OCCN(CCOC(=O)C)C(=O)[C@@H]1CC2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C
  • InChI=1S/C24H31N3O5/c1-15(28)31-9-7-27(8-10-32-16(2)29)24(30)18-11-20-19-5-4-6-21-23(19)17(13-25-21)12-22(20)26(3)14-18/h4-6,13,18,20,22,25H,7-12,14H2,1-3H3/t18-,20?,22-/m1/s1
  • Key:LXWNLFQDQZPCPP-HCNFZCTASA-N

AWD 52-39, also known as N,N-diacetoxyethyl-9,10-dihydrolysergamide, is a drug described as a "nootropic" (cognitive enhancer) of the lysergamide family related to lysergic acid diethylamide (LSD) that was never marketed. [1] [2] [3] It was under development by Arzneimittelwerk Dresden, but development was discontinued. [2] The effects of AWD 52-39 in preclinical studies have been reported. [3] [4] [5] [6] The drug has been found to enhance learning and memory and to produce antidepressant-like effects in rodents. [1] It appears to act upon vascular serotonin receptors. [5] The chemical synthesis and stereochemistry of AWD 52-39 have been described. [7] The drug was first described in the scientific literature by 1989. [3]

See also

References

  1. 1 2 Hoffmann W, Rostock A, Siegemund C, Bartsch R (1990). "Effects of the novel compound AWD 52-39 on behavioral test methods for evaluation of memory-enhancing drugs". European Journal of Pharmacology. 183 (4): 1480. doi:10.1016/0014-2999(90)94625-8 . Retrieved 15 October 2025.
  2. 1 2 Froestl W, Pfeifer A, Muhs A (2013). "Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs". Journal of Alzheimer's Disease. 34 (1): 1–114. doi:10.3233/JAD-121729. PMID   23186990.
  3. 1 2 3 Hoffman W, Rostock A, Siegemund C, Bartsch R (April 1989). "AWD 52-39, an ergot derivative with potential nootropic activity". Activitas Nervosa Superior. 31 (1): 56–57. PMID   2782003.
  4. ↑ Brust P, Jordan K (August 1992). "Effects of the nootropic AWD 52-39 on the blood-brain transfer of leucine, choline and glucose in rats after 14-d exposure to ethanol". Die Pharmazie. 47 (8): 616–620. PMID   1438514.
  5. 1 2 Müller H, Glusa E (February 1992). "Effect of AWD 52-39 on vasoconstriction induced by noradrenaline and 5-hydroxytryptamine in vitro and in vivo in rats". Die Pharmazie. 47 (2): 137–139. PMID   1635923.
  6. ↑ Brust P (1991). "Blood-brain barrier transport under different physiological and pathophysiological circumstances including ischemia". Experimental Pathology. 42 (4): 213–219. doi:10.1016/s0232-1513(11)80068-x. PMID   1959581.
  7. ↑ Dopke W, Heidenbluth K, Hempel R, Zeigan D, Mugge C (1995). "Synthese und Stereochemie von AWD 52-39" [Synthesis and Stereochemistry of AWD-52-39.]. Pharmazie (in German). 50 (5): 351–354.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.